Oral dosage forms comprising progesterone and methods of making and using the same

Details for Australian Patent Application No. 2006249349 (hide)

Owner Teva Women's Health, Inc.

Inventors Ahmed, Salah U.; Diliberti, Charles E.; Vattikonda, Chandra; Gorukanti, Sudhir R.; Gupta, Sanjeev K.

Agent Davies Collison Cave

Pub. Number AU-B-2006249349

PCT Pub. Number WO2006/128057

Priority 60/684,557 26.05.05 US

Filing date 26 May 2006

Wipo publication date 30 November 2006

Acceptance publication date 12 January 2012

International Classifications

A61K 9/48 (2006.01) Medicinal preparations characterised by special physical form - Preparations in capsules, e.g. of gelatin, of chocolate

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 31/57 (2006.01) - substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone

Event Publications

31 January 2008 PCT application entered the National Phase

  PCT publication WO2006/128057 Priority application(s): WO2006/128057

19 August 2010 Alteration of Name

  The name of the applicant has been altered to Teva Women's Health, Inc.

12 January 2012 Application Accepted

  Published as AU-B-2006249349

10 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006249350-Thyromimetics for the treatment of fatty liver diseases

2006249348-Novel phosphinic acid-containing thyromimetics